Page 203 - Eceptor News Today

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug - used to treat constipation - may be able to boost our ability to think more clearly.

A new study used the available nucleotide sequence data on the NCBI COVID-19 database and estimated the global prevalence of adaptive and prolonged infections' mutations in the RBD of the S protein.

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

COVID-19 not only causes symptoms characteristic of a typical respiratory disorder, but has also been known to trigger a wide range of other symptoms in people who had been infected, some lasting even long after individuals test negative for the virus.

Researchers from the CDC have investigated differences in seroprevalence across pediatric age groups to estimate an infection to case ratio.

Myasthenia gravis is the commonest disorder of neuromuscular transmission. Autoimmune myasthenia gravis needs to be distinguished from congenital myasthenic syndromes.

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

A review article published in the journal Frontiers in Physiology by researchers affiliated with the Federal University of São Paulo in Brazil discusses the mechanisms whereby SARS-CoV-2 damages the kidneys, potentially serving as a basis for further research in pursuit of treatments to prevent severe renal problems and even chronic kidney disease in COVID-19 patients.